Author

Keiko Ishimoto

Observed name: Ishimoto, Keiko

Institution: VLP Therapeutics (United States)

Observed institution: VLP Therapeutics (United States)

ORCID: 0000-0002-9188-6702

Observed ORCID: 0000-0002-9188-6702

OpenAlex ID: A5035861574

Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing an anchored RBD: A randomized, observer-blind phase 1 study

2023 · Wataru Akahata, Takashi Sekida, et al. · Cell Reports Medicine · 46

saRNA vaccine expressing membrane-anchored RBD elicits broad and durable immunity against SARS-CoV-2 variants of concern

2023 · Mai Komori, Takuto Nogimori, et al. · Nature Communications · 39

Abstract 2894: Alphavirus replicon expressing IL-12 reprograms tumor-associated macrophages and neutrophils and induces anti-tumor immunity

2026 · Forrest Bowling, Momoko Ishikawa, et al. · Cancer Research

Alphavirus replicon particle expressing IL-12 reprograms tumor-associated macrophages and neutrophils and induces anti-tumor immunity

2025 · Momoko Ishikawa, Dhanya K Nambiar, et al. · bioRxiv (Cold Spring Harbor Laboratory)

Works count: 5

Citation count: 85

H-index: 2

I10-index: 2